Associate Professor of Obstetrics and Gynecology, University Alabama
Obstetrics & Gynecology
Dr. Ronald D. Alvarez, MD
|
|
Give Review
Ronald Alvarez is an expert in the field of Obstetrics & Gynecology. He studied medicine at University of Alabama Medical Center. University of Alabama Medical Center is ranked 37 in research and 17 in primary care medicine He received awards:"America's Top Doctors", "America's Top Doctors for Cancer", "Fellow (FACS)" and "Fellow (FACOG)". Doctor Ronald D. Alvarez, MD is a published MD. He published 99 publications, including: 'Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- The role of racial genetic admixture with endometrial Cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study.
- Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian Cancer.
- Endpoints in clinical trials: What do patients consider important? A survey of the Ovarian Cancer National Alliance.
- In Assessing Surrogate Clinical Trial End Points: Drug Safety Is a Requisite.
- Detection of Somatic TP53 Mutations in Tampons of Patients With High-Grade Serous Ovarian Cancer.
- Folate and Vitamin B12 May Play a Critical Role in Lowering the HPV 16 Methylation-Associated Risk of Developing Higher Grades of CIN.
- SGO guidance document for clinical trial designs in ovarian Cancer: A changing paradigm.
- Report on NRG Oncology and the GOG Partners Program.
- Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian Cancer.
- Corrigendum to: "Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurren...
- An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian Cancer.
- Inhibition of Wnt/ß-catenin pathway by niclosamide: A therapeutic target for ovarian Cancer.
- A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial o...
- Ovarian Cancer Clinical Trial Endpoints: Society of Gynecologic Oncology White Paper.
- Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian Cancer patients.
- Ovarian Cancer, version 2.2013.
- A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenoVirus (CRAd), in patients with recurrent ovarian...
- Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian Cancer.
- Folate and folate receptor alpha antagonists mechanism of action in ovarian Cancer.
- Histone deacetylase inhibitor AR-42 enhances E7-specific CD8(+) T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.
- Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.
- Chemotherapy Acts as an Adjuvant to Convert the Tumor Microenvironment into a Highly Permissive State for Vaccination-Induced Antitumor Immunity.
- We need a new paradigm in gynecologic Cancer care: SGO proposes solutions for delivery, quality and reimbursement policies.
- The Gynecologic Oncology Group (GOG) Report.
- Enhancement of Cisplatin-Mediated Apoptosis in Ovarian Cancer Cells through Potentiating G2/M Arrest and p21 Upregulation by Combinatorial Epigallocatechin Gallate and...
- Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian Cancer cells through hTERT and Bcl-2 down-regulation.
- The Effect of the APPRISE Mandate on Use of Erythropoiesis-Stimulating Agents and Transfusion Rates in Patients With Ovarian Cancer Receiving Chemotherapy.
- A Lower Degree of PBMC L1 Methylation Is Associated with Excess Body Weight and Higher HOMA-IR in the Presence of Lower Concentrations of Plasma Folate.
- Ovarian Cancer, Version 3.2012.
- Human papillomavirus: what every provider should know.
- Smoothened antagonists reverse taxane resistance in ovarian Cancer.
- A Phase I Clinical Trial of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Patients with Recurrent Gynecologic Cancer.
- Completed versus aborted radical hysterectomy for node-positive stage IB Cervical cancer in the modern era of chemoradiation therapy.
- A Dietary Pattern Associated with LINE-1 Methylation Alters the Risk of Developing Cervical Intraepithelial Neoplasia.
- Stem cell pathways contribute to clinical chemoresistance in ovarian Cancer.
- Targeting the Notch Ligand Jagged1 in Both Tumor Cells and Stroma in Ovarian Cancer.
- Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies.
- A cohort study evaluating robotic versus laparotomy surgical outcomes of obese women with endometrial Carcinoma.
- A higher degree of LINE-1 methylation in peripheral blood mononuclear cells, a one-carbon nutrient related epigenetic alteration, is associated with a lower risk of de...
- Gynecologic Oncology Group (GOG) Report.
- A New Generation of Serotype Chimeric Infectivity-Enhanced Conditionally Replicative Adenovirals: The Safety Profile of Ad5/3-Δ24 in Advance of a Phase I ...
- A higher degree of methylation of the HPV 16 E6 gene is associated with a lower likelihood of being diagnosed with Cervical intraepithelial neoplasia.
- Epithelial ovarian Cancer.
- A phase I study of a tropism-modified conditionally replicative adenoVirus for recurrent malignant gynecologic diseases.
- Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women w...
- Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian Cancer patients: results of a three-arm Phase I study.
- Novel infectivity-enhanced oncolytic adenovirus with a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian Cancer.
- Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian Cancer model.
- Phase II trial of ixabepilone as second-line treatment in advanced endometrial Cancer: gynecologic oncology group trial 129-P.
- Lower risk of Cervical intraepithelial neoplasia in women with high plasma folate and sufficient vitamin B12 in the post-folic acid fortification era.
- Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenoVirus, in anticipation of a phase I clinical trial in patients with re...
- Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian Cancer.
- Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal Carcinoma with the potential for dose escala...
- An outpatient intraperitoneal chemotherapy regimen for advanced ovarian Cancer.
- A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian Carcinoma.
- A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian Cancer.
- Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal Cancers.
- Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination.
- Lynch syndrome in women less than 50 years of age with endometrial Cancer.
- Lipoxygenase pathway receptor expression in ovarian Cancer.
- Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human Cervical cancer model.
- Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian Carcinoma cell lines.
- Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian Cancer.
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic Cancers.
- New advances in vaccine technology and improved Cervical cancer prevention.
- A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian Cancer ex vivo syste...
- Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian Carcinoma using a novel ex vivo tissue slice model.
- Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenoVirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ...
- Integrating the Gynecologic Oncology Group and Gynecologic Cancer SPOREs--a square peg in a round hole or fits like a glove?
- Treatment of ovarian Cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).
- A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian Carcinoma following the failure of second-line therapy.
- Icodextrin enhances survival in an intraperitoneal ovarian Cancer murine model utilizing gene therapy.
- Intraperitoneal chemotherapy and the NCI clinical announcement.
- Gene therapy for ovarian Cancer.
- Circumventing recombination events encountered with production of a clinical-grade adenoviral vector with a double-expression cassette.
- Unilateral Cervical cancer in a patient with cervix duplex.
- Inflammatory pseudotumor of pelvic lymph nodes.
- Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian Cancer.
- Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian Cancer ...
- Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a Cervical cancer model.
- Ovarian Cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy.
- AdenoViruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery.
- Immune responses to human papillomavirus in genital tract of women with Cervical cancer.
- A prospective evaluation of "see and treat" in women with HSIL Pap Smear results: is this an appropriate strategy?
- A novel ex vivo model system for evaluation of conditionally replicative adenoViruses therapeutic efficacy and toxicity.
- Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian Cancer.
- High-risk human papillomavirus and Cervical intraepithelial neoplasia at time of atypical squamous cells of undetermined significance cytologic results in a population...
- The impact of aborted radical hysterectomy in patients with cervical Carcinoma.
- Gene transfer to Cervical cancer with fiber-modified adenoviruses.
- Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian Carcinoma.
- Transport across a polarized monolayer of Caco-2 cells by transferrin receptor-mediated adenoVirus transcytosis.
- Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian Cancer gene therapy.
- Optical detection of high-grade Cervical intraepithelial neoplasia in vivo: results of a 604-patient study.
- Transcriptional blocks limit adenoviral replication in primary Ovarian tumor.
- Expression of sperm protein 17 (Sp17) in ovarian Cancer.
- Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series.
- The role of radical parametrectomy in the treatment of occult cervical Carcinoma after extrafascial hysterectomy.
- Complications of indwelling venous access devices in patients with gynecologic malignancies.
Schools
Louisiana State Univ School Of Medicine In New Orleans
University Ala
Procedures Preformed
- Colposcopy
- Destruction or Excision of Lesion of Cervix (incl. LEEP)
- Destruction or Excision of Vaginal Lesions
- Dilation and Curettage
- View All
Conditions Treated
- Atrophic Vaginitis
- Carcinoma in Situ
- Cervical Cancer
- Cervical Polyps
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Fellow (FACS)
- Fellow (FACOG)
Education
-
University of Alabama Medical Center -
Louisiana State University School of Medicine in New Orleans
Hospital
-
University of Alabama Hospital -
Brookwood Medical Center
Drug Facts
| NPI NUMBER | 1689623167 | |
| NPPES Provider LastName | ALVAREZ | |
| NPPES Provider FirstName | RONALD | |
| NPPES Provider ZIPCode | 35233 | |
| NPPES Provider State | AL | |
| Specialty Description | Obstetrics/Gynecology | |
| Total Claim Count | 465.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 64.0 | |
| Percent Opioid Claims | 13.76 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1689623167 |
| Last Name Of The Provider | ALVAREZ |
| First Name Of The Provider | RONALD |
| View All |
Similar Doctors
|
|
Dr. Edward E. Partridge Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rowell S. Ashford II, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy R. Gregory, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles A. Leath III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Groesbeck P. Parham, MD |
|
|
Dr. Jacob M. Estes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William E. Somerall Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kellie Matthews, MD |
|
|
Dr. Dean Veren, MD
This Doctor is OpenDoctor Recommended.
|